Clinical trial
Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN-188 for the Treatment of Moderate to Severe Migraine Headache Without Aura
NCT00959751 is registered in ClinicalTrials.gov with NeurAxon Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN-188 for the Treatment of Moderate to Severe Migraine Headache Without Aura
- Lead sponsor
- NeurAxon Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 31, 2009
- Completion date
- March 31, 2010
- Enrollment
- 195 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.